The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Amisulpride and olanzapine followed by open-label treatment with clozapine in first-episode schizophrenia and schizophreniform disorder (OPTiMiSE): a three-phase switching study
Open accessAbstract
BACKGROUND No established treatment algorithm exists for patients with schizophrenia. Whether switching antipsychotics or early use of clozapine improves outcome in (first-episode) schizophrenia is unknown. METHODS This three-phase study was done in 27 centres, consisting of general hospitals and psychiatric specialty clinics, in 14 European countries and Israel. Patients aged 18-40 years who met criteria of the DSM-IV for schizophrenia, schizophreniform disorder, or schizoaffective disorder were treated for 4 weeks with up to 800 mg/day amisulpride orally in an open-label design (phase 1). Patients who did not meet symptomatic remission criteria at 4 weeks were randomly assigned to continue amisulpride or switch to olanzapine (≤20 mg/day) during a 6-week double-blind phase, with patients and staff masked to treatment allocation (phase 2). Randomisation was done online by a randomisation website; the application implemented stratification by site and sex, and applied the minimisation method for randomisation. Patients who were not in remission at 10 weeks were given clozapine (≤900 mg/day) for an additional 12 weeks in an open-label design (phase 3). The primary outcome was the number of patients who achieved symptomatic remission at the final visits of phases 1, 2, and 3, measured by intention-to-treat analysis. Data were analysed with a generalised linear mixed model, with a logistic link and binomial error distribution. This trial is registered with ClinicalTrials.gov, number NCT01248195, and closed to accrual. FINDINGS Between May 26, 2011, and May 15, 2016, we recruited 481 participants who signed informed consent. Of the 446 patients in the intention-to-treat sample, 371 (83%) completed open-label amisulpride treatment, and 250 (56%) achieved remission after phase 1. 93 patients who were not in remission continued to the 6-week double-blind switching trial, with 72 (77%) patients completing the trial (39 on olanzapine and 33 on amisulpride); 15 (45%) patients on amisulpride versus 17 (44%) on olanzapine achieved remission (p=0·87). Of the 40 patients who were not in remission after 10 weeks of treatment, 28 (70%) started on clozapine; 18 (64%) patients completed the 12-week treatment, and five (28%) achieved remission. The number of serious adverse events did not differ between the treatment arms in phase 2: one patient on olanzapine was admitted to hospital because of an epileptic seizure, and one patient on amisulpride was admitted to hospital twice because of exacerbations of psychotic symptoms. Over the course of the trial, two serious suicide attempts were reported. INTERPRETATION For most patients in the early stages of schizophrenia, symptomatic remission can be achieved using a simple treatment algorithm comprising the sequential administration of amisulpride and clozapine. Since switching to olanzapine did not improve outcome, clozapine should be used after patients fail a single antipsychotic trial-not until two antipsychotics have been tried, as is the current recommendation. FUNDING European Commission Seventh Framework Program.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Leucht, S., Cipriani, A., Spineli, L., Mavridis, D., Örey, D., Richter, F., Samara, M., Barbui, C., Engel, R. R., Geddes, J. R., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60733-3 · Cited by 2,561
Self-citation
Cited by
Barnes, T. R., Drake, R., Paton, C., Cooper, S. J., Deakin, B., Ferrier, I. N., Gregory, C. J., Haddad, P. M., Howes, O. D., Jones, I., et al. (2020) · Journal of Psychopharmacology · doi:10.1177/0269881119889296 · Cited by 606
Self-citationPotkin, S. G., Kane, J. M., Correll, C. U., Lindenmayer, J.-P., Agid, O., Marder, S. R., Olfson, M., & Howes, O. D. (2020) · npj Schizophrenia · doi:10.1038/s41537-019-0090-z · Cited by 359
García-Gutiérrez, M. S., Navarrete, F., Gasparyan, A., Austrich-Olivares, A., Sala, F., & Manzanares, J. (2020) · Biomolecules · doi:10.3390/biom10111575 · Cited by 306
Dose-response meta-analysis of antipsychotic drugs for acute schizophrenia
Leucht, S., Crippa, A., Siafis, S., Patel, M. X., Orsini, N., & Davis, J. M. (2020) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2019.19010034 · Cited by 301
Self-citationSiskind, D., Orr, S., Sinha, S., Yu, O., Brijball, B., Warren, N., MacCabe, J. H., Smart, S. E., & Kisely, S. (2022) · The British Journal of Psychiatry · doi:10.1192/bjp.2021.61 · Cited by 255
Metadata
- Authors
- Kahn, R. S., Winter van Rossum, I., Leucht, S., McGuire, P., Lewis, S. W., Leboyer, M., Arango, C., Dazzan, P., Drake, R., Heres, S., Díaz-Caneja, C. M., Rujescu, D., Weiser, M., Galderisi, S., Glenthøj, B., Eijkemans, M. J. C., Fleischhacker, W. W., Kapur, S., Sommer, I. E., Kahn, R. S., Sommer, I. E., Winter-van Rossum, I., Somers, M., Ywema, P. C., Kapur, S., McGuire, P., Leboyer, M., Meyer-Lindenberg, A., Lewis, S. W., Leucht, S., Arango, C., Fleischhacker, W. W., Meijering, A. L., Petter, J., Van de Brug, R., Schotsman, J., Zwerver, J., Peuskens, J., De Hert, M., Thys, E., Hranov, L. G., Hranov, V., Libiger, J., Köhler, R., Mohr, P., Glenthoj, B., Broberg, B., Düring, S., Baandrup, L., Jamain, S., Heres, S., Rujescu, D., Giegling, I., Weiser, M., Bar Heim, M., Davidson, M., Galderisi, S., Bucci, P., Mucci, A., Rybakowski, J., Remlinger-Molenda, A., Gonen, I., Radu, P., Díaz-Marsá, M., Rodriguez, A., Palomo, T., Rodriguez-Jimenez, R., García-Portilla, P., Bernardo, M., Bobes, J., Vilares Oliveira, C., Berger, G., Wildt, C., Dazzan, P., Perez-Iglesias, R., Drake, R., Gregory, S., Wilson, D., Díaz-Caneja, C. M., & Eijkemans, M. J. C.
- Venue
- The Lancet Psychiatry
- Publisher
- Elsevier BV
- Published
- 2018-10
- Volume
- 5
- Issue
- 10
- Pages
- 797-807
- ISSN
- 2215-0366 (ISSN-L)
- OpenAlex
- W2886339749
- Cited by
- 193
- References
- 1
- FWCI
- 17.34
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Amisulpride and olanzapine followed by open-label treatment with clozapine in first-episode schizophrenia and schizophreniform disorder (OPTiMiSE): a three-phase switching study. https://app.cochat.ai/papers/10.1016/s2215-0366(18)30252-9
- The paper
- Kahn, R. S., Winter van Rossum, I., Leucht, S., McGuire, P., Lewis, S. W., Leboyer, M., Arango, C., Dazzan, P., Drake, R., Heres, S., Díaz-Caneja, C. M., Rujescu, D., Weiser, M., Galderisi, S., Glenthøj, B., Eijkemans, M. J. C., Fleischhacker, W. W., Kapur, S., Sommer, I. E., . . . Eijkemans, M. J. C. (2018). Amisulpride and olanzapine followed by open-label treatment with clozapine in first-episode schizophrenia and schizophreniform disorder (OPTiMiSE): a three-phase switching study. The Lancet Psychiatry. https://doi.org/10.1016/s2215-0366(18)30252-9
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.